Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성순희 | * |
dc.contributor.author | 문병인 | * |
dc.contributor.author | 조민선 | * |
dc.contributor.author | 임우성 | * |
dc.contributor.author | 박상희 | * |
dc.date.accessioned | 2018-11-21T16:30:07Z | - |
dc.date.available | 2018-11-21T16:30:07Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 1526-8209 | * |
dc.identifier.issn | 1938-0666 | * |
dc.identifier.other | OAK-23387 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246641 | - |
dc.description.abstract | Using the 7 immunohistochemical surrogate markers, we tried to classify 200 TNBCs into 4 molecular subtypes; luminal androgen receptor, mesenchymal, basal-like immune-activated, and basal-like immune-suppressive types. Our results showed that each subtype had significant differences in clinicopathological characteristics and prognosis. Introduction: Recently, Burstein et al identified 4 stable molecular subtypes of triple negative breast cancer (TNBC) by mRNA profiling: luminal androgen receptor (LAR), mesenchymal (MES), basal-like immune-activated (BLIA), and basallike immune-suppressive (BLIS) types. The purpose of this study was to assess the feasibility of immunohistochemistry (IHC) surrogate panel in classifying the TNBC molecular subtypes using a large cohort of TNBC retrieved from a single institution. Materials and Methods: IHC for androgen receptor [AR], claudin-3, E-cadherin, cytokeratin 5/6 [CK5/6], epidermal growth factor receptor [EGFR], indoleamine 2,3-dioxygenase 1 [IDO1], and Forkhead box C1 [FOXC1] were performed using the tissue microarray constructed from 200 TNBC samples. Results: The 200 TNBCs were classified as LAR (AR(+), n = 22; 11.0%), MES (claudin 3(-) and/or E-cadherin(-), n = 23; 11.5%), basal-like (CK5/6(+) and/or EGFR(+), n = 85; 42.5%), mixed (n = 60; 30%), and unclassifiable type (n = 10; 5%). LAR type was associated with older patient age, apocrine histologic features, low density of stromal tumor-infiltrating lymphocytes (TIL), and low Ki-67 labeling index. MES type was associated with tumor cell discohesiveness and metaplastic features. Basal-like type was associated with younger patient age, high histologic grade, high stromal TIL density, and high Ki-67 labeling index. Basal-like TNBCs were further classified as BLIA (IDO1(+) and FOXC1(+), n = 27) or BLIS type (IDO1-and FOXC1(+), n = 11). BLIS type was associated with large tumor size and low stromal TIL density, which had the worst prognostic outcome among 4 subtypes. Conclusion: The IHC surrogate panel may define TNBC subtypes with distinct clinicopathologic characteristics and prognostic significance. | * |
dc.language | English | * |
dc.publisher | CIG MEDIA GROUP, LP | * |
dc.subject | Basal-like immune-activated | * |
dc.subject | Basal-like immune-suppressed | * |
dc.subject | Immunohistochemistry | * |
dc.subject | Molecular subtype | * |
dc.subject | Triple negative breast carcinoma | * |
dc.title | Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 18 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | E1123 | * |
dc.relation.lastpage | E1132 | * |
dc.relation.journaltitle | CLINICAL BREAST CANCER | * |
dc.identifier.doi | 10.1016/j.clbc.2018.03.012 | * |
dc.identifier.wosid | WOS:000445702400052 | * |
dc.identifier.scopusid | 2-s2.0-85046851065 | * |
dc.author.google | Kim, Sewha | * |
dc.author.google | Moon, Byung-In | * |
dc.author.google | Lim, Woosung | * |
dc.author.google | Park, Sanghui | * |
dc.author.google | Cho, Min Sun | * |
dc.author.google | Sung, Sun Hee | * |
dc.contributor.scopusid | 성순희(7202731948;58455037400) | * |
dc.contributor.scopusid | 문병인(7101878644;56119062300) | * |
dc.contributor.scopusid | 조민선(13205279200) | * |
dc.contributor.scopusid | 임우성(27167744500) | * |
dc.contributor.scopusid | 박상희(12041890800) | * |
dc.date.modifydate | 20240220112152 | * |